爱朋医疗涨2.15%，成交额7776.60万元，主力资金净流入674.73万元

Company Overview - Aipeng Medical, established on October 30, 2001, and listed on December 13, 2018, specializes in the development, production, and sales of medical devices in pain management and nasal care [1][2] - The company's revenue composition includes 59.73% from pain management products, 29.40% from nasal and upper airway products, and 10.87% from other sources [1] Stock Performance - As of August 29, Aipeng Medical's stock price increased by 2.15% to 33.80 CNY per share, with a total market capitalization of 4.26 billion CNY [1] - Year-to-date, the stock has risen by 92.43%, with a recent decline of 0.76% over the last five trading days, a 9.88% increase over the last 20 days, and a 27.31% increase over the last 60 days [1] Financial Performance - For the first half of 2025, Aipeng Medical reported a revenue of 159 million CNY, a year-on-year decrease of 11.31%, and a net profit attributable to shareholders of -19.38 million CNY, a decrease of 317.90% [2] - The company has distributed a total of 113 million CNY in dividends since its A-share listing, with 16.36 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, 2025, Aipeng Medical had 32,400 shareholders, an increase of 57.18% from the previous period, with an average of 2,711 circulating shares per shareholder, a decrease of 36.33% [2] - Notably, the fund "Huaxia Innovation Future Mixed (LOF)" has exited the list of the top ten circulating shareholders [3]